Amivantamab: Treating<i>EGFR</i>Exon 20–Mutant Cancers With Bispecific Antibody-Mediated Receptor Degradation
Authors: Jens Köhler, Pasi A. Jänne
Journal: Journal of Clinical Oncology (2021)

Article Tools UNDERSTANDING THE PATHWAY Article Tools OPTIONS & TOOLS Export Citation Track Citation Add To Favorites Rights & Permissions COMPANION ARTICLES Amivantamab in EGFR Exon 20 Insertion–Mutated Non–Small-Cell Lung Cancer Progressing on Platinum Chemotherapy: Initial Results From the CHRYSALIS Phase I Study. August 02, 2021 ARTICLE CITATION DOI: 10.1200/JCO.21.01494 Journal of Clinical Oncology - published online before print August 2, 2021 PMID: 34339261 Amivantamab: Treating EGFR Exon 20–Mutant Cancers With Bispecific Antibody-Mediated Receptor Degradation Jens Köhler , MD1xJens KöhlerSearch for articles by this author and Pasi A. Jänne , MD, PhD1,2,3xPasi A. JänneSearch for articles by this author Show More 1Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA2Chen-Huang Center for EGFR Mutant Lung Cancers, Boston, MA3Belfer Center for Applied Cancer Sciences, Boston, MA https://doi.org/10.1200/JCO.21.01494 First Page Full Text PDF Figures and Tables © 2021 by American Society of Clinical OncologyAUTHOR CONTRIBUTIONSConception and design: All authorsCollection and assembly of data: All authorsData analysis and interpretation: All authorsManuscript writing: All authorsFinal approval of manuscript: All authorsAccountable for all aspects of the work: All authorsAUTHORS' DISCLOSURES OF POTENTIAL CONFLICTS OF INTERESTAmivantamab: Treating EGFR Exon 20–Mutant Cancers With Bispecific Antibody-Mediated Receptor DegradationThe following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript. For more information about ASCO's conflict of interest policy, please refer to www.asco.org/rwc or ascopubs.org/jco/authors/author-center.Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments).Jens KöhlerConsulting or Advisory Role: Boehringer IngelheimResearch Funding: LillyPasi A. JänneStock and Other Ownership Interests: Gatekeeper Pharmaceuticals, Loxo OncologyConsulting or Advisory Role: Pfizer, Boehringer Ingelheim, AstraZeneca, Merrimack, Chugai Pharma, Roche/Genentech, LOXO, Mirati Therapeutics, Araxes Pharma, Ignyta, Lilly, Takeda, Novartis, Biocartis, Voronoi, SFJ Pharmaceuticals Group, Sanofi, Biocartis, Daiichi Sankyo, Silicon Therapeutics, Nuvalent Inc, Eisai, Bayer, Syndax, AbbVie, Allorion Therapeutics, Accutar BiotechResearch Funding: AstraZeneca, Astellas Pharma, Daiichi Sankyo, Lilly, Boehringer Ingelheim, Puma Biotechnology, Takeda, Revolution MedicinesPatents, Royalties, Other Intellectual Property: I am a coinventor on a DFCI-owned patent on EGFR mutations licensed to Lab Corp. I receive postmarketing royalties from this inventionNo other potential conflicts of interest were reported. Companion Amivantamab in EGFR Exon 20 Insertion–Mutated Non–Small-Cell Lung Cancer Progressing on Platinum Chemotherapy: Initial Results From the CHRYSALIS Phase I Study